Literature DB >> 33224799

Novel analysis of prognosis of young patients with stage II differentiated thyroid cancer based on AJCC 8.0 and 6.0 criteria to implement the staging system.

Yihui Huang1, Ling Zhou1, Wen Zeng2, Sichao Chen1, Wei Zhou1, Wei Wei3, Chao Zhang4, Di Hu1, Min Wang1, Zeming Liu1, Liang Guo1.   

Abstract

BACKGROUND: The incidence of thyroid cancer among young adults is increasing; however, the clinical challenges specific to this population, such as diagnosis, reduced healthcare access, and inconsistent care, have received limited attention. Here, we conducted a subgroup analysis on a series of relatively young patients with differentiated thyroid carcinomas (DTCs), focusing on those with distant metastases at stage II, to obtain a deeper understanding of the factors influencing survival.
METHODS: Information on <45- or <55-year-old patients at any T/N stage with distant metastasis (M1) was extracted from the SEER database according to the staging system in the 6th and 8th American Joint Committee on Cancer (AJCC) editions, respectively. Patient mortality was evaluated using Cox proportional hazards regression analyses and Kaplan-Meier analyses with log-rank tests.
RESULTS: Both cancer-specific and all-cause mortality rates per 1,000 person-years for patients ≥35 years old significantly differed from those of patients <35 years old. DTC-specific survival curves also significantly differed between these age groups, according to both the AJCC 6.0 and 8.0-based analyses (P=0.0017 and P<0.001, respectively), as did patient survival curves (P=0.0003, P<0.001, respectively). The multivariate Cox regression model also revealed that poor OS was strongly predicted by race (P<0.001) in the analysis based on the criteria of 8th AJCC staging system.
CONCLUSIONS: Age is a risk factor for disease-specific and overall survival (OS) in young patients with stage II DTC, and young male patients exhibited poorer survival than females. Race also emerged as a potential risk factor for young patients in stage II. These findings offer guidance for improving the older and newer versions of the AJCC staging system. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Surveillance, Epidemiology, and End Results (SEER); Thyroid cancer; distant metastasis; prognosis; stage II

Year:  2020        PMID: 33224799      PMCID: PMC7667068          DOI: 10.21037/gs-20-46

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  16 in total

1.  Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database.

Authors:  Ryan K Orosco; Timon Hussain; Kevin T Brumund; Deborah K Oh; David C Chang; Michael Bouvet
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

2.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

3.  An expanded view of risk-group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

4.  The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland.

Authors:  Iain J Nixon; Monica M Whitcher; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Thyroid       Date:  2012-07-24       Impact factor: 6.568

5.  A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry.

Authors:  Hop S Tran Cao; Lily E Johnston; David C Chang; Michael Bouvet
Journal:  Surgery       Date:  2012-04-11       Impact factor: 3.982

6.  Reevaluating the prognostic significance of age in differentiated thyroid cancer.

Authors:  Samuel L Oyer; Valerie A Smith; Eric J Lentsch
Journal:  Otolaryngol Head Neck Surg       Date:  2012-03-30       Impact factor: 3.497

7.  The impact of age and gender on papillary thyroid cancer survival.

Authors:  J Jonklaas; G Nogueras-Gonzalez; M Munsell; D Litofsky; K B Ain; S T Bigos; J D Brierley; D S Cooper; B R Haugen; P W Ladenson; J Magner; J Robbins; D S Ross; M C Skarulis; D L Steward; H R Maxon; S I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2012-04-10       Impact factor: 5.958

8.  The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States.

Authors:  Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Brian C-H Chiu; Peter Angelos; Raymon H Grogan
Journal:  Ann Surg Oncol       Date:  2013-03-17       Impact factor: 5.344

9.  Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin.

Authors:  Naris Nilubol; Lisa Zhang; Electron Kebebew
Journal:  Thyroid       Date:  2013-05-28       Impact factor: 6.568

10.  Prognosis of a rare subtype of thyroid cancer: Spindle cell thyroid carcinoma.

Authors:  Zeming Liu; Qiuyang Zhao; Wen Zeng; Shuntao Wang; Yiquan Xiong; Hui Guo; Tao Huang; Hongtao Cheng; Liang Guo
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.